---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009853"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:29:43.005335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aclaris sells OLUMIANT royalties to OMERS for up to $31.5M upfront and milestones

## Summary
- Received $26.5M upfront; eligible for up to $5M additional based on 2024 sales milestones for OLUMIANT.
- Sold portion of future OLUMIANT royalties from Lilly and 100% of remaining anniversary milestone payments.
- Non-dilutive transaction; proceeds to strengthen balance sheet and support strategic priorities.
- Aclaris continues strategic review; will invest in internal immuno-inflammatory pipeline programs.
- OLUMIANT (baricitinib) is Lilly's treatment for alopecia areata; royalty term runs through remainder of license.

## SEC filing metadata
- accession: 0001558370-24-009853
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024009853/0001558370-24-009853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024009853/acrs-20240716x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009853
- JSON: https://secwatch.observer/filing/0001558370-24-009853.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.